



Nanotechnology Solutions for Radioisotope detection



The Opportunity

Radioisotope measurements provide critical enabling tools for understanding the underlying basis of disease

Global

- \$15B
- Projected growth rate 5 %

US

- >\$2.5B
- Gov't, Industrial, Academic, Medical


Target

- \$400 M
- Research laboratory section of US market



Pain Points

- Sample incompatibility
- Spatial/temporal limitations
- Waste generation




Exemplar Problem	RIs cannot be measured in living cells
------------------	--



Our Solution

Proprietary core-shell nanoscintillators



IP Status 1 Patent Application (10/2017)
 1 Provisional Patent Application (1/2019)
 2 Disclosures (2018)


Team




Craig A. Aspinwall, Ph.D.
Co-Founder and CTO



Colleen M. Janczak, Ph.D.
Co-Founder and COO



CEO



VP/Director
Sales and Marketing




CBO/
VP Business Strategy

Our Products


Available for immediate sales

5 Current Users




nanoSCINT

His-tag nanoSPA
Protein Y nanoSPA
Protein G nanoSPA
Anti-rabbit IgG nanoSPA
Biotin nanoSPA




nanoSCINT



nanoSPA

Business model

Customer Recruitment



Customer Retention



Financials

	Year 1	Year 2	Year 3
Revenue	590,000	2,400,000	8,600,000
GP%	56%	54%	52%
Cost of Goods Sold	260,000	1,100,000	4,100,000
Units Sold	515	1526	7447
G + A	800,000	910,000	1,200,000
Net Income	(470,000)	340,000	2,000,000
EBITA	(480,000)	340,000	3,200,000


3-Year Sales Revenue Projections

Revenue is imminent

Break-even point at 18 months

Exit strategy

Acquisition within 5 years based on sales and market share captured





Opportunities for early investors

- Early revenues
- A large US and global market
- Broadly applicable technology
- Societal and environmental impact
- High returns on comparable entities

Thank you!
Questions?